You just read:

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

News provided by

Astellas Pharma Inc.

Feb 11, 2019, 17:00 ET